Chaemsaithong P, Sahota D, Pooh RK, et al. - Researchers examined if the European‐derived biomarker multiples of the median (MoM) formulae for risk assessment of preterm preeclampsia (PE) can be applied in seven Asian populations, spanning the east, southeast and south regions of the continent. In addition, quality‐assurance (QA) assessment of the biomarker measurements was performed and criteria for prospective ongoing QA assessment of biomarker measurements were established. In this prospective, non‐intervention, multicenter study, they assessed 4,023 singleton pregnancies, at 11 to 13 + 6 weeks' gestation, in 11 recruiting centers in China, Hong Kong, India, Japan, Singapore, Taiwan and Thailand. As Asian women differ from Caucasian women in anthropometric parameters, there were significant differences in biomarker MoM values for PE screening, especially mean arterial pressure (MAP) and placental growth factor MoMs, in Asian populations compared with the expected values based on European‐derived formulae. As per QA assessment tools, consistently lower MAP MoM values were evident among women in all centers than expected; however, these were within 10% of the expected value. At all sites except one, uterine artery pulsatility index (UtA‐PI) MoM values were within 10% of the expected value. Systematically 10% lower than the expected value was observed for most placental growth factor MoM values, except for those derived from a South Asian population, which were 37% higher. For reporting reliable and consistent patient‐specific risks for preterm PE, there is necessity for adjustment for additional factors or development of Asian‐specific formulae for the calculation of biomarker MoMs. In addition, this work emphasize the importance and need for regular quality assessment of biomarker values.